Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while laser hair removal improves quality of life for women with facial hirsutism, emotional benefits diminish over 30 months and additional treatments may be necessary to maintain improvements.

This study found that spironolactone reduced testosterone production and urinary 17-ketosteroid excretion, leading to a decrease in hair growth rate and a change in hair texture in women.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.

This review discusses the complex interaction between androgens and hair follicle biology, highlighting the need for a better understanding to improve hirsutism treatments, but reports no new results.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This review discusses the management of hirsutism and acne in women with polycystic ovary syndrome, highlighting the partial effectiveness of current treatments and suggesting a combined approach of medication and hair removal.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This review highlights that idiopathic hirsutism is characterized by local hyperandrogenization affecting hair growth, without other signs of hyperandrogenism, and shows no new results; racial differences in prevalence are noted but not in androgenic steroids.

This study found that hirsutism significantly negatively impacts quality of life, with self-assessed severity more strongly linked to quality-of-life impact and depressive symptoms than clinician assessments.

This study found that normal mode ruby laser treatment for hirsutism is well tolerated and results in significant hair count reduction for at least six months, with multiple treatments offering greater effects.

This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

This study found that flutamide was more effective than finasteride in reducing hair growth in women with hirsutism over a one-year period.

This study found that a combination therapy of Diane 35 with finasteride was more effective at reducing hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome after 3 months compared to Diane 35 alone.

This study found that finasteride significantly reduced hirsutism scores in women with idiopathic hirsutism and PCOS, despite no changes in serum androgen levels.

This review discusses the physiology of hair growth, common abnormal patterns of hirsutism, and examines differential diagnoses and treatment options, but provides no new clinical findings.

In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

In this study, hirsutism was found to have the most significant negative impact on health-related quality of life among Iranian women with polycystic ovary syndrome.

This review summarizes hair growth aspects, treatment options, and management strategies for hirsutism in women with polycystic ovary syndrome, without presenting new clinical findings.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

In this study, ketoconazole treatment improved acne in all women and reduced hirsutism in some, but it caused several side effects and requires careful monitoring.

In this study, women with hirsutism and amenorrhea showed lower serum estradiol and sex hormone binding globulin concentrations but higher levels of unbound testosterone compared to normal individuals.

This study suggests that combination drug therapy with spironolactone and either oral contraceptives or dexamethasone effectively manages unresponsive hirsutism, with eight of nine patients achieving satisfactory clinical responses.

This letter discusses the first reported case of serious liver damage linked to the use of flutamide for hirsutism in a woman, highlighting a potential risk for hepatotoxicity with this treatment.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.

In this study, PCOS was the most common cause of hirsutism among Turkish women, but about 17% had idiopathic hyperandrogenemia with no clear cause identified.

This study reports that once neoplastic causes are excluded, functional hirsutism can be effectively treated with low-dose dexamethasone, oral contraceptives, and spironolactone.